Systemic immune-inflammation index as a potential biomarker to monitor ulcerative colitis

References

• Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74. doi: 10.1038/s41572-020-0205-x.
   PubMed Web of Science ®Google Scholar
• Plevris N, Lees CW. Disease monitoring in FIT bowel disease: evolving principles and possibilities. Gastroenterology. 2022;162(5):1456–1475.e1. doi: 10.1053/j.gastro.2022.01.024.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi: 10.1053/j.gastro.2020.12.031.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Sandborn WJ, Feagan BG, et al. Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE study. Aliment Pharmacol Ther. 2022;56(3):463–476. doi: 10.1111/apt.16937.
   PubMed Web of Science ®Google Scholar
• Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. Development and validation of the Nancy histological index for UC. Gut. 2017;66(1):43–49. doi: 10.1136/gutjnl-2015-310187.
   PubMed Web of Science ®Google Scholar
• Reinink AR, Lee TC, Higgins PD. Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis. 2016;22(8):1859–1869. doi: 10.1097/MIB.0000000000000816.
   PubMed Web of Science ®Google Scholar
• Jangi S, Holmer AK, Dulai PS, et al. Risk of relapse in patients with ulcerative colitis with persistent endoscopic healing: a durable treatment endpoint. J Crohns Colitis. 2021;15(4):567–574. doi: 10.1093/ecco-jcc/jjaa184.
   PubMed Web of Science ®Google Scholar
• Shah SC, Colombel J-F, Sands BE, et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(9):1245–1255.e8. doi: 10.1016/j.cgh.2016.01.015.
   PubMed Web of Science ®Google Scholar
• Park S, Abdi T, Gentry M, et al. Histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis: systematic review and Meta-Analysis. Am J Gastroenterol. 2016;111(12):1692–1701. doi: 10.1038/ajg.2016.418.
   PubMed Web of Science ®Google Scholar
• Bryant RV, Burger DC, Delo J, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65(3):408–414. doi: 10.1136/gutjnl-2015-309598.
   PubMed Web of Science ®Google Scholar
• Seong G, Song JH, Kim JE, et al. Histologic activity and steroid use history are risk factors of clinical relapse in ulcerative colitis with Mayo endoscopic subscore of 0 or 1. Inflamm Bowel Dis. 2023;29(2):238–244. doi: 10.1093/ibd/izac075.
   PubMed Web of Science ®Google Scholar
• Wang H, Fewings I, Bornman L, et al. Histologic remission (NANCY index) is superior to endoscopic mucosal healing in predicting relapse free survival in patients with ulcerative colitis in clinical and endoscopic remission. J Clin Gastroenterol. 2023;57(5):494–500. doi: 10.1097/MCG.0000000000001681.
   PubMed Web of Science ®Google Scholar
• Spiceland CM, Lodhia N. Endoscopy in inflammatory bowel disease: role in diagnosis, management, and treatment. World J Gastroenterol. 2018;24(35):4014–4020. doi: 10.3748/wjg.v24.i35.4014.
   PubMed Web of Science ®Google Scholar
• Liu D, Saikam V, Skrada KA, et al. Inflammatory bowel disease biomarkers. Med Res Rev. 2022;42(5):1856–1887. doi: 10.1002/med.21893.
   PubMed Web of Science ®Google Scholar
• Sakurai T, Saruta M. Positioning and usefulness of biomarkers in inflammatory bowel disease. Digestion. 2023;104(1):30–41. doi: 10.1159/000527846.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Peyrin-Biroulet L, Danese S, et al. Approaches to integrating biomarkers into clinical trials and care pathways as targets for the treatment of inflammatory bowel diseases. Gastroenterology. 2019;157(4):1032–1043.e1. doi: 10.1053/j.gastro.2019.06.018.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426–431. doi: 10.1136/gut.2005.069476.
   PubMed Web of Science ®Google Scholar
• Hart L, Chavannes M, Kherad O, et al. Faecal calprotectin predicts endoscopic and histological activity in clinically quiescent ulcerative colitis. J Crohns Colitis. 2020;14(1):46–52. doi: 10.1093/ecco-jcc/jjz107.
   PubMed Web of Science ®Google Scholar
• Kawashima K, Oshima N, Kishimoto K, et al. Low fecal calprotectin predicts histological healing in patients with ulcerative colitis with endoscopic remission and leads to prolonged clinical remission. Inflamm Bowel Dis. 2023;29(3):359–366. doi: 10.1093/ibd/izac095.
   Web of Science ®Google Scholar
• Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(11):1746–1754. doi: 10.1002/ibd.20920.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Ebana R, Kudo T, et al. Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease. J Gastroenterol. 2022;57(5):344–356. doi: 10.1007/s00535-022-01856-w.
   PubMed Web of Science ®Google Scholar
• Grant RK, Jones G-R, Plevris N, et al. The ACE (albumin, CRP and endoscopy) index in acute colitis: a simple clinical index on admission that predicts outcome in patients with acute ulcerative colitis. Inflamm Bowel Dis. 2021;27(4):451–457. doi: 10.1093/ibd/izaa088.
   PubMed Web of Science ®Google Scholar
• Croft A, Lord A, Radford-Smith G. Markers of systemic inflammation in acute attacks of ulcerative colitis: what level of C-reactive protein constitutes severe colitis? J Crohns Colitis. 2022;16(7):1089–1096. doi: 10.1093/ecco-jcc/jjac014.
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Niwa M, Takedatsu H, et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1304–1310. doi: 10.3748/wjg.v22.i3.1304.
   PubMed Web of Science ®Google Scholar
• Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42(6):788–791. doi: 10.1136/gut.42.6.788.
   PubMed Web of Science ®Google Scholar
• Takedatsu H, Mitsuyama K, Fukunaga S, et al. Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease. J Gastroenterol Hepatol. 2018;33(9):1603–1607. doi: 10.1111/jgh.14140.
   Web of Science ®Google Scholar
• Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. BMJ. 1988;297(6656):1105–1106. doi: 10.1136/bmj.297.6656.1105.
   PubMed Web of Science ®Google Scholar
• Shinzaki S, Matsuoka K, Iijima H, et al. Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. J Crohns Colitis. 2017;11(1):84–91. doi: 10.1093/ecco-jcc/jjw132.
   PubMed Web of Science ®Google Scholar
• Yasutomi E, Inokuchi T, Hiraoka S, et al. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. Sci Rep. 2021;11(1):11086. doi: 10.1038/s41598-021-90441-x.
   PubMed Web of Science ®Google Scholar
• Kawamoto A, Takenaka K, Hibiya S, et al. Serum leucine-rich α2 glycoprotein: a novel biomarker for small bowel mucosal activity in crohn’s disease. Clin Gastroenterol Hepatol. 2022;20(5):e1196–e200. doi: 10.1016/j.cgh.2021.06.036.
   PubMed Web of Science ®Google Scholar
• Akpinar MY, Ozin YO, Kaplan M, et al. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio predict mucosal disease severity in ulcerative colitis. J Med Biochem. 2018;37(2):155–162. doi: 10.1515/jomb-2017-0050.
   PubMed Web of Science ®Google Scholar
• Torun S, Tunc BD, Suvak B, et al. Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity. Clin Res Hepatol Gastroenterol. 2012;36(5):491–497. doi: 10.1016/j.clinre.2012.06.004.
   PubMed Web of Science ®Google Scholar
• Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–6222. doi: 10.1158/1078-0432.CCR-14-0442.
   PubMed Web of Science ®Google Scholar
• Luo H, He L, Zhang G, et al. Normal reference intervals of Neutrophil-To-Lymphocyte ratio, Platelet-To-Lymphocyte ratio, Lymphocyte-To-Monocyte ratio, and systemic immune inflammation index in healthy adults: a large Multi-Center study from Western China. Clin Lab. 2019;65(3). doi: 10.7754/Clin.Lab.2018.180715.
   Web of Science ®Google Scholar
• Lin JX, Lin JP, Xie JW, et al. Complete blood count-based inflammatory score (CBCS) is a novel prognostic marker for gastric cancer patients after curative resection. BMC Cancer. 2020;20(1):11. doi: 10.1186/s12885-019-6466-7.
   PubMed Web of Science ®Google Scholar
• Yang J, Guo X, Wu T, et al. Prognostic significance of inflammation-based indexes in patients with stage III/IV colorectal cancer after adjuvant chemoradiotherapy. Medicine (Baltimore). 2019;98(6):e14420. doi: 10.1097/MD.0000000000014420.
   PubMed Web of Science ®Google Scholar
• Murthy P, Zenati MS, Al Abbas AI, et al. Prognostic value of the systemic Immune-Inflammation index (SII) after neoadjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol. 2020;27(3):898–906. doi: 10.1245/s10434-019-08094-0.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen B, Wang L, et al. Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: a meta-analysis. Medicine (Baltimore). 2019;98(3):e13788. doi: 10.1097/MD.0000000000013788.
   PubMed Web of Science ®Google Scholar
• Kim Y, Choi H, Jung SM, et al. Systemic immune-inflammation index could estimate the cross-sectional high activity and the poor outcomes in immunosuppressive drug-naive patients with antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton). 2019;24(7):711–717. doi: 10.1111/nep.13491.
   PubMed Web of Science ®Google Scholar
• Xie Y, Zhuang T, Ping Y, et al. Elevated systemic immune inflammation index level is associated with disease activity in ulcerative colitis patients. Clin Chim Acta. 2021;517:122–126. doi: 10.1016/j.cca.2021.02.016.
   PubMed Web of Science ®Google Scholar
• Lin H, Bai Z, Wu Q, et al. Inflammatory indexes for assessing the severity and disease progression of ulcerative colitis: a single-center retrospective study. Front Public Health. 2022;10:851295. doi: 10.3389/fpubh.2022.851295.
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. Third european evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–670. doi: 10.1093/ecco-jcc/jjx008.
   PubMed Web of Science ®Google Scholar
• Fu W, Fu H, Ye W, et al. Peripheral blood neutrophil-to-lymphocyte ratio in inflammatory bowel disease and disease activity: a meta-analysis. Int Immunopharmacol. 2021;101(Pt B):108235. doi: 10.1016/j.intimp.2021.108235.
   PubMed Web of Science ®Google Scholar
• Chen J-H, Zhai E-T, Yuan Y-J, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–6272. doi: 10.3748/wjg.v23.i34.6261.
   PubMed Web of Science ®Google Scholar
• Zhang M-H, Wang H, Wang H-G, et al. Effective immune-inflammation index for ulcerative colitis and activity assessments. World J Clin Cases. 2021;9(2):334–343. doi: 10.12998/wjcc.v9.i2.334.
   PubMed Web of Science ®Google Scholar
• Pakoz ZB, Ustaoglu M, Vatansever S, et al. Serum Immune-Inflammation index assessment in the patients with ulcerative colitis. Gastroenterol Res Pract. 2022;2022:9987214–9987215. doi: 10.1155/2022/9987214.
   PubMed Web of Science ®Google Scholar
• Le Berre C, Ricciuto A, Peyrin-Biroulet L, et al. Evolving short- and Long-Term goals of management of inflammatory bowel diseases: getting it right, making it last. Gastroenterology. 2022;162(5):1424–1438. doi: 10.1053/j.gastro.2021.09.076.
   PubMed Web of Science ®Google Scholar
• Wilkens R, Dolinger M, Burisch J, et al. Point-of-Care testing and home testing: pragmatic considerations for widespread incorporation of stool tests, serum tests, and intestinal ultrasound. Gastroenterology. 2022;162(5):1476–1492. doi: 10.1053/j.gastro.2021.10.052.
   PubMed Web of Science ®Google Scholar